Julian Wanner

Julian Wanner

Auto-generated profile, based on publicly available information

Julian Wanner

Hasso Plattner Institute, Digital Engineering Faculty, University of Potsdam, Germany (J.S.W., M.K., H.O.H.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BJBradley Jermy
Bradley Jermy
KLKristi Läll
Kristi Läll
BWBrooke N. Wolford
Brooke N. Wolford
YWYing Wang
Ying Wang
KZKristina Zguro
Kristina Zguro
SRSamuli Ripatti
Samuli Ripatti
Polygenic scores (PGSs) offer the ability to predict genetic risk for complex diseases across the life course; a key benefit over short-term prediction models. To produce risk estimates relevant to clinical and public health decision-making, it is important to account for varying effects due to age and sex. Here, we develop a novel framework to estimate country-, age-, and sex-specific estimates of cumulative incidence stratified by PGS for 18 high-burden diseases. We integrate PGS associations from seven studies in four countries (N = 1,197,129) with disease incidences from the Global Burden of Disease. PGS has a significant sex-specific effect for asthma, hip osteoarthritis, gout, coronary heart disease and type 2 diabetes (T2D), with all but T2D exhibiting a larger effect in men. PGS has a larger effect in younger individuals for 13 diseases, with effects decreasing linearly with age. We show for breast cancer that, relative to individuals in the bottom 20% of polygenic risk, the top 5% attain an absolute risk for screening eligibility 16.3 years earlier. Our framework increases the generalizability of results from biobank studies and the accuracy of absolute risk estimates by appropriately accounting for age- and sex-specific PGS effects. Our results highlight the potential of PGS as a screening tool which may assist in the early prevention of common diseases.

25 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HHHenrike O. Heyne
Henrike O. Heyne
FPFanny-Dhelia Pajuste
Fanny-Dhelia Pajuste
JWJulian Wanner
Julian Wanner
JOJennifer Ibimina Daniel Onwuchekwa
Jennifer Ibimina Daniel Onwuchekwa
RMReedik Mägi
Reedik Mägi
MDMark J. Daly
Mark J. Daly
A diagnosis of epilepsy has significant consequences for an individual but is often challenging in clinical practice. Novel biomarkers are thus greatly needed. Here, we investigated how common genetic factors (epilepsy polygenic risk scores, [PRSs]) influence epilepsy risk in detailed longitudinal electronic health records (EHRs) of > 700k Finns and Estonians. We found that a high genetic generalized epilepsy PRS (PRSGGE) increased risk for genetic generalized epilepsy (GGE) (hazard ratio [HR] 1.73 per PRSGGE standard deviation [SD]) across lifetime and within 10 years after an unspecified seizure event. The effect of PRSGGE was significantly larger on idiopathic generalized epilepsies, in females and for earlier epilepsy onset. Analogously, we found significant but more modest focal epilepsy PRS burden associated with non-acquired focal epilepsy (NAFE). Here, we outline the potential of epilepsy specific PRSs to serve as biomarkers after a first seizure event.

30 September 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ZYZhiyu Yang
Zhiyu Yang
FPFanny-Dhelia Pajuste
Fanny-Dhelia Pajuste
KZKristina Zguro
Kristina Zguro
YCYipeng Cheng
Yipeng Cheng
DKDanielle E. Kurant
Danielle E. Kurant
AGAndrea Ganna
Andrea Ganna
Understanding disease progression is of high biological and clinical interest. Unlike disease susceptibility, whose genetic basis has been abundantly studied, less is known about the genetics of disease progression and its overlap with disease susceptibility. Considering nine common diseases (n cases ranging from 11,980 to 124,682) across seven biobanks, we systematically compared genetic architectures of susceptibility and progression, defined as disease-specific mortality. We identified only one locus substantially associated with disease-specific mortality and showed that, at a similar sample size, more genome-wide significant loci can be identified in a genome-wide association study of disease susceptibility. Variants substantially affecting disease susceptibility were weakly or not associated with disease-specific mortality. Moreover, susceptibility polygenic scores (PGSs) were weak predictors of disease-specific mortality, while a PGS for general lifespan was substantially associated with disease-specific mortality for seven of nine diseases. We explored alternative definitions of disease progression and found that genetic signals for macrovascular complications in type 2 diabetes overlap with similar phenotypes in the general population; however, these effects are attenuated. Overall, our findings indicate limited similarity in genetic effects between disease susceptibility and disease-specific mortality, suggesting that larger sample sizes, different measures of progression, or the integration of related phenotypes from the general population is needed to identify the genetic underpinnings of disease progression.

27 November 2023 in medRxiv
Verified
Preprint
Open access
PDF file
HHHenrike O. Heyne
Henrike O. Heyne
FPFanny-Dhelia Pajuste
Fanny-Dhelia Pajuste
JWJulian Wanner
Julian Wanner
JOJennifer I. Daniel Onwuchekwa
Jennifer I. Daniel Onwuchekwa
RMReedik Mägi
Reedik Mägi
MDMark J. Daly
Mark J. Daly
A diagnosis of epilepsy has significant consequences for an individual but is often challenging in clinical practice. Novel biomarkers are thus greatly needed. Here, we investigated how common genetic factors (epilepsy polygenic risk scores, [PRSs]) influence epilepsy risk in detailed longitudinal electronic health records (EHRs) of > 360k Finns spanning up to 50 years of individuals’ lifetimes. Individuals with a high genetic generalized epilepsy PRS (PRS GGE ) in FinnGen had an increased risk for genetic generalized epilepsy (GGE) (hazard ratio [HR] 1.55 per PRS GGE standard deviation [SD]) across their lifetime and after unspecified seizure events. Effect sizes of epilepsy PRSs were comparable to effect sizes in clinically curated data supporting our EHR-derived epilepsy diagnoses. Within 10 years after an unspecified seizure, the GGE rate was 37% when PRS GGE > 2 SD compared to 5.6% when PRS GGE < –2 SD. The effect of PRS GGE was even larger on GGE subtypes of idiopathic generalized epilepsy (IGE) (HR 2.1 per SD PRS GGE ). We further report significantly larger effects of PRS GGE on epilepsy in females and in younger age groups. Analogously, we found significant but more modest focal epilepsy PRS burden associated with non-acquired focal epilepsy (NAFE). We found PRS GGE specifically associated with GGE in comparison with >2000 independent diseases while PRS NAFE was also associated with other diseases than NAFE such as back pain. Here, we show that epilepsy specific PRSs have good discriminative ability after a first seizure event i.e. in circumstances where the prior probability of epilepsy is high outlining a potential to serve as biomarkers for an epilepsy diagnosis.

16 December 2025 in Circulation
Verified
Journal Article
Open access
JWJulian S Wanner
Julian S Wanner
MKMaren Krafft
Maren Krafft
TNTeemu Niiranen
Teemu Niiranen
DZDominic S Zimmerman
Dominic S Zimmerman
PEPatrick T Ellinor
Patrick T Ellinor
HHHenrike O Heyne
Henrike O Heyne
BACKGROUND: Atrial fibrillation and other cardiac arrhythmias pose a major public health burden, but prevention remains difficult. We investigated a genetic variant that we found to act like a natural lifelong cardiac sodium channel blockade. METHODS: We studied the impact of the Finnish-enriched SCN5A missense variant (rs45620037 [T220I]) on cardiac arrhythmias, associated mortality, and ECG phenotypes in a multicohort observational study with >1 million individuals across 3 cohorts (FinnGen, UK Biobank, and Health 2000). RESULTS: We identified protective effects of T220I on multiple common cardiac arrhythmias, most notably atrial fibrillation (cause-specific hazard ratio [HR], 0.56 [95% CI, 0.50–0.63]; P <0.0001), but also ventricular premature depolarization or ventricular tachycardia, as well as increasing susceptibility to conduction-slowing conditions, such as sick sinus syndrome (mostly in older age groups). Overall, T220I conveyed protection from death resulting from cardiac arrhythmia (HR, 0.65 [95% CI, 0.46–0.92]; P =0.015) without a significant effect on overall mortality risk (HR, 0.92; P =0.27). T220I heterozygosity had similar electrophysiological effects as some pharmacological sodium channel blockers, such as significantly shortening QT intervals (−7.49 ms [95% CI, −10.07 to −4.91] ms; P =0.0037; n=3188) in the Health 2000 cohort, which we replicated in the UK Biobank (n=66 616). In addition, T220I protected from (left) heart failure and dilated cardiomyopathy. After myocardial infarction, we found that T220I increased mortality risk, consistent with known sodium channel blocker effects, which, however, normalized to baseline 10 to 15 years after myocardial infarction. We found that T220I could lower a high genetic burden (ie, a high polygenic score) for atrial fibrillation to population average. CONCLUSIONS: The SCN5A T220I variant, consistent with a previously described weak loss-of-function effect, acted like a genetic proxy for cardiac sodium channel blockade. This enabled us to gain new potentially clinically relevant insights for pharmacological sodium channel blockade, such as after myocardial infarction, which would be too risky to investigate with clinical trials. Our findings may also inspire redesign of cardiac sodium channel blockers.

19 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJulian Wanner
Julian Wanner
LCLuis Kuhn Cuellar
Luis Kuhn Cuellar
LRLuiselotte Rausch
Luiselotte Rausch
KBKenneth Wayne Berendzen
Kenneth Wayne Berendzen
FWFriederike Wanke
Friederike Wanke
SNSven Nahnsen
Sven Nahnsen
Here we report nextflow-root ( nf-root ), a novel best-practice pipeline for deep learning-based analysis of fluorescence microscopy images of plant root tissue, aimed at studying hormonal mechanisms associated with cell elongation, given the vital role that plant hormones play in the development and growth of plants. This bioinformatics pipeline performs automatic identification of developmental zones in root tissue images, and analysis of apoplastic pH measurements of tissue zones, which is useful for modeling plant hormone signaling and cell physiological responses. Mathematical models of physiological responses of plant hormones, such as brassinolide, have been successfully established for certain root tissue types, by evaluating apoplastic pH via fluorescence imaging. However, the generation of data for this modeling is time-consuming, as it requires the manual segmentation of tissue zones and evaluation of large amounts of microscopy data. We introduce a high-throughput, highly reproducible Nextflow pipeline based on nf-core standards that automates tissue zone segmentation by implementing a deep-learning module, which deploys deterministically trained (i.e. bit-exact reproducible) convolutional neural network models, and augments the segmentation predictions with measures of prediction uncertainty and model interpretability , aiming to facilitate result interpretation and verification by experienced plant biologists. To train our segmentation prediction models, we created a publicly available dataset composed of confocal microscopy images of A. thaliana root tissue using the pH-sensitive fluorescence indicator, and manually annotated segmentation masks that identify relevant tissue zones. We applied this pipeline to analyze exemplary data, and observed a high statistical similarity between the manually generated results and the output of nf-root . Our results indicate that this approach achieves near human-level performance, and significantly reduces the time required to analyze large volumes of data, from several days to hours.